Abstract
INTRODUCTION: Chemoradiotherapy after maximal debulking surgery is the standard of care for patients with glioblastoma. This study reviews patient outcomes at our centre. Analysis has been performed based on well-established prognostic criteria in glioblastoma, and other tumour and patient-related factors. METHOD: Patients with glioblastoma operated on between 1st April 2010 and 31st March 2013 at NHNN, and then treated with chemoradiotherapy at UCLH, were included in the study cohort. Outcome data based on patient and tumour characteristics were collected from the electronic records and radiotherapy planning systems, and were censored on 31st December 2013. RESULTS: 62 patients were studied (32 female, 30 male) with a median overall survival of 18 months, and median progression-free survival of 10 months. 75% patients were alive at 1 year; 42% at 2 years. PS had a significant effect of survival (p = 0.019). Trends were seen with other standard prognostic criteria: type of surgery (p = 0.087), age (p = 0.110), MGMT status (p = 0.292). Female patients survived significantly longer than males (p = 0.038). There was no effect of tumour size or location, or time from surgery to chemoradiotherapy. Analysis of molecular phenotype showed no correlation between survival and Ki67, EGFR amplification, or PTEN loss. CONCLUSION: The standard prognostic criteria in glioblastoma show the expected trends in our patients, but male patients appear to do significantly worse. There is no correlation with other investigated characteristics including tumour size and molecular phenotype. The benefit of starting chemoradiotherapy earlier has not been shown in our patient population. Overall, our outcomes at least match those in the literature.